What is Zacks Research’s Estimate for Pfizer Q3 Earnings?

Pfizer Inc. (NYSE:PFE) – Analysts at Zacks Research raised their Q3 2025 EPS estimates for Pfizer in a research report issued to clients and investors on Monday, February 24th. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will post earnings of $0.90 per share for the quarter, up from their previous forecast of $0.83. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Zacks Research also issued estimates for Pfizer’s FY2025 earnings at $2.94 EPS, Q3 2026 earnings at $0.93 EPS, Q4 2026 earnings at $0.89 EPS, FY2026 earnings at $3.03 EPS and FY2027 earnings at $2.98 EPS.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.10 EPS.

PFE has been the subject of several other reports. Wolfe Research assumed coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Finally, Citigroup decreased their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Price Performance

Pfizer stock opened at $26.76 on Wednesday. The company has a market capitalization of $151.62 billion, a price-to-earnings ratio of 18.98, a PEG ratio of 0.64 and a beta of 0.64. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer has a 12 month low of $24.48 and a 12 month high of $31.54. The stock’s 50 day moving average is $26.33 and its 200-day moving average is $27.37.

Institutional Investors Weigh In On Pfizer

A number of hedge funds have recently made changes to their positions in the stock. Heck Capital Advisors LLC bought a new position in Pfizer in the 4th quarter valued at approximately $49,000. Leigh Baldwin & CO. LLC acquired a new position in shares of Pfizer during the fourth quarter worth $1,726,000. Armis Advisers LLC bought a new position in shares of Pfizer in the 4th quarter valued at $215,000. Hall Capital Management Co. Inc. acquired a new stake in shares of Pfizer during the 4th quarter valued at $484,000. Finally, Ameriflex Group Inc. bought a new stake in Pfizer during the 4th quarter worth $230,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.06% of the stock is owned by insiders.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.43%. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.